Building on a long and growing list of collaborations, artificial intelligence (AI) firm Exscientia (Nasdaq: EXAI) has agreed terms for a new deal with French pharma major Sanofi (Euronext: SAN).
The research collaboration and license agreement, which could be worth billions to the Oxford-based company, covers the development of up to 15 novel small molecule candidates across oncology and immunology.
Exscientia brings to the table its end-to-end AI-driven platform, which uses actual patient samples.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze